Karuna Therapeutics (KRTX) Stock Forecast, Price Target & Predictions
KRTX Stock Forecast
Karuna Therapeutics stock forecast is as follows: an average price target of $257.50 (represents a -21.93% downside from KRTX’s last price of $329.83) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
KRTX Price Target
The average price target for Karuna Therapeutics (KRTX) is $257.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $330.00 to $150.00. This represents a potential -21.93% downside from KRTX's last price of $329.83.
KRTX Analyst Ratings
According to 6 Wall Street analysts, Karuna Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KRTX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Karuna Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 26, 2023 | Raghuram Selvaraju | H.C. Wainwright | $330.00 | $317.00 | 4.10% | 0.05% |
| Jan 05, 2023 | - | Piper Sandler | $285.00 | $198.46 | 43.61% | -13.59% |
| Aug 12, 2022 | Yatin Suneja | Guggenheim | $330.00 | $261.31 | 26.29% | 0.05% |
| Aug 08, 2022 | Paul Matteis | Stifel Nicolaus | $260.00 | $241.19 | 7.80% | -21.17% |
| Apr 27, 2022 | - | Mizuho Securities | $190.00 | $120.50 | 57.68% | -42.39% |
| Aug 05, 2021 | Jason McCarthy | Maxim Group | $150.00 | $117.81 | 27.32% | -54.52% |
The latest Karuna Therapeutics stock forecast, released on Dec 26, 2023 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $330.00, which represents a 4.10% increase from the stock price at the time of the forecast ($317.00), and a 0.05% increase from KRTX last price ($329.83).
Karuna Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $330.00 |
| Last Closing Price | $329.83 | $329.83 | $329.83 |
| Upside/Downside | -100.00% | -100.00% | 0.05% |
In the current month, the average price target of Karuna Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Karuna Therapeutics's last price of $329.83. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 28, 2023 | Canaccord Genuity | Buy | Buy | Hold |
| Dec 26, 2023 | H.C. Wainwright | - | Neutral | Downgrade |
| Mar 02, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Jan 05, 2023 | Piper Sandler | - | Overweight | Initialise |
| Aug 08, 2022 | Wedbush | Outperform | Outperform | Hold |
| Jul 14, 2022 | SVB Leerink | - | Outperform | Initialise |
Karuna Therapeutics's last stock rating was published by Canaccord Genuity on Dec 28, 2023. The company gave KRTX a "Buy" rating, the same as its previous rate.
Karuna Therapeutics Financial Forecast
Karuna Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $5.28M | $81.00K | $36.96M |
| Avg Forecast | $56.95M | $44.30M | $32.42M | $20.53M | $53.04M | $3.02M | $562.50K | $3.31M | $862.42K | $1.26M | $416.88K | $7.14K | $916.67K | $7.78M |
| High Forecast | $56.95M | $44.30M | $32.42M | $20.53M | $53.04M | $3.02M | $562.50K | $3.31M | $1.28M | $1.26M | $416.88K | $7.14K | $916.67K | $7.78M |
| Low Forecast | $56.95M | $44.30M | $32.42M | $20.53M | $53.04M | $3.02M | $562.50K | $3.31M | $441.51K | $1.25M | $416.88K | $7.14K | $916.67K | $7.78M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 738.91% | 0.09% | 4.75% |
Karuna Therapeutics's average Quarter revenue forecast for Jun 23 based on 8 analysts is $416.88K, with a low forecast of $416.88K, and a high forecast of $416.88K. KRTX's average Quarter revenue forecast represents a -92.10% decrease compared to the company's last Quarter revenue of $5.28M (Dec 22).
Karuna Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-136.22M | $-119.91M | $-85.04M | $-80.70M | $-27.72M |
| Avg Forecast | $-11.39M | $-8.86M | $-6.48M | $-4.11M | $-10.61M | $-604.37K | $-112.50K | $-662.50K | $-172.48K | $-251.04K | $-83.38K | $-1.43K | $-183.33K | $-1.56M |
| High Forecast | $-11.39M | $-8.86M | $-6.48M | $-4.11M | $-10.61M | $-604.37K | $-112.50K | $-662.50K | $-88.30K | $-250.52K | $-83.38K | $-1.43K | $-183.33K | $-1.56M |
| Low Forecast | $-11.39M | $-8.86M | $-6.48M | $-4.11M | $-10.61M | $-604.37K | $-112.50K | $-662.50K | $-256.08K | $-251.56K | $-83.38K | $-1.43K | $-183.33K | $-1.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 542.61% | 1438.15% | 59549.02% | 440.20% | 17.82% |
undefined analysts predict KRTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Karuna Therapeutics's previous annual EBITDA (undefined) of $NaN.
Karuna Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 14 |
| Net Income | - | - | - | - | - | - | - | - | - | $-119.12M | $-103.16M | $-76.21M | $-69.05M | $-27.96M |
| Avg Forecast | $-62.10M | $-75.76M | $-87.99M | $-99.10M | $-77.44M | $-119.84M | $-114.23M | $-107.70M | $-100.13M | $-103.01M | $-104.49M | $-84.63M | $-80.84M | $-65.52M |
| High Forecast | $-62.10M | $-75.76M | $-87.99M | $-99.10M | $-77.44M | $-119.84M | $-114.23M | $-89.75M | $-80.41M | $-75.19M | $-104.49M | $-84.63M | $-80.84M | $-65.52M |
| Low Forecast | $-62.10M | $-75.76M | $-87.99M | $-99.10M | $-77.44M | $-119.84M | $-114.23M | $-114.88M | $-127.06M | $-125.20M | $-104.49M | $-84.63M | $-80.84M | $-65.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 0.99% | 0.90% | 0.85% | 0.43% |
Karuna Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KRTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Karuna Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 14 |
| SG&A | - | - | - | - | - | - | - | - | - | $32.27M | $27.42M | $24.31M | $19.13M | $20.06M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Karuna Therapeutics's average Quarter SG&A projection for Dec 23 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to KRTX last annual SG&A of $32.27M (Sep 23).
Karuna Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 14 |
| EPS | - | - | - | - | - | - | - | - | - | $-3.16 | $-2.75 | $-2.22 | $-2.13 | $-0.94 |
| Avg Forecast | $-1.64 | $-2.01 | $-2.33 | $-2.62 | $-2.05 | $-3.17 | $-3.02 | $-2.85 | $-2.65 | $-2.73 | $-2.77 | $-2.24 | $-2.14 | $-1.73 |
| High Forecast | $-1.64 | $-2.01 | $-2.33 | $-2.62 | $-2.05 | $-3.17 | $-3.02 | $-2.38 | $-2.13 | $-1.99 | $-2.77 | $-2.24 | $-2.14 | $-1.73 |
| Low Forecast | $-1.64 | $-2.01 | $-2.33 | $-2.62 | $-2.05 | $-3.17 | $-3.02 | $-3.04 | $-3.36 | $-3.31 | $-2.77 | $-2.24 | $-2.14 | $-1.73 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 0.99% | 0.99% | 1.00% | 0.54% |
According to undefined Wall Street analysts, Karuna Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KRTX previous annual EPS of $NaN (undefined).
Karuna Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.40 | $3.67 | 817.50% | Buy |
| INZY | Inozyme Pharma | $3.13 | $14.67 | 368.69% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.40 | $7.00 | 191.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| TERN | Terns Pharmaceuticals | $6.17 | $14.25 | 130.96% | Buy |
| MREO | Mereo BioPharma Group | $3.53 | $6.75 | 91.22% | Buy |
| CYTK | Cytokinetics | $50.22 | $83.23 | 65.73% | Buy |
| DYN | Dyne Therapeutics | $28.39 | $43.88 | 54.56% | Buy |
| EWTX | Edgewise Therapeutics | $31.44 | $45.00 | 43.13% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |